Compugen reported $1.35M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Arca Biopharma USD 4.6M 4.1M Mar/2026
aTyr Pharma 69.82M 9.83M Jun/2026
Bio Path 677K 547K Mar/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Compugen USD 1.35M 399K Mar/2026
Immunic 197K 222K Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
RedHill Biopharma USD 89.8K 31.69M Jun/2024
TherapeuticsMD USD 20K 25K Sep/2023